TY - JOUR
T1 - Cross-sectional exploration of plasma biomarkers of alzheimer’s disease in down syndrome
T2 - Early data from the longitudinal investigation for enhancing down syndrome research (life-dsr) study
AU - Hendrix, James A.
AU - Airey, David C.
AU - Britton, Angela
AU - Burke, Anna D.
AU - Capone, George T.
AU - Chavez, Ronelyn
AU - Chen, Jacqueline
AU - Chicoine, Brian
AU - Costa, Alberto C.S.
AU - Dage, Jeffrey L.
AU - Doran, Eric
AU - Esbensen, Anna
AU - Evans, Casey L.
AU - Faber, Kelley M.
AU - Foroud, Tatiana M.
AU - Hart, Sarah
AU - Haugen, Kelsey
AU - Head, Elizabeth
AU - Hendrix, Suzanne
AU - Hillerstrom, Hampus
AU - Kishnani, Priya S.
AU - Krell, Kavita
AU - Ledesma, Duvia Lara
AU - Lai, Florence
AU - Lott, Ira
AU - Ochoa-Lubinoff, Cesar
AU - Mason, Jennifer
AU - Nicodemus-Johnson, Jessie
AU - Proctor, Nicholas Kyle
AU - Pulsifer, Margaret B.
AU - Revta, Carolyn
AU - Rosas, H. Diana
AU - Rosser, Tracie C.
AU - Santoro, Stephanie
AU - Schafer, Kim
AU - Scheidemantel, Thomas
AU - Schmitt, Frederick
AU - Skotko, Brian G.
AU - Stasko, Melissa R.
AU - Talboy, Amy
AU - Torres, Amy
AU - Wilmes, Kristi
AU - Woodward, Jason
AU - Zimmer, Jennifer A.
AU - Feldman, Howard H.
AU - Mobley, William
N1 - Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2021/5/1
Y1 - 2021/5/1
N2 - With improved healthcare, the Down syndrome (DS) population is both growing and aging rapidly. However, with longevity comes a very high risk of Alzheimer’s disease (AD). The LIFE-DSR study (NCT04149197) is a longitudinal natural history study recruiting 270 adults with DS over the age of 25. The study is designed to characterize trajectories of change in DS-associated AD (DS-AD). The current study reports its cross-sectional analysis of the first 90 subjects enrolled. Plasma biomarkers phosphorylated tau protein (p-tau), neurofilament light chain (NfL), amyloid β peptides (Aβ1-40, Aβ1-42), and glial fibrillary acidic protein (GFAP) were undertaken with previously published methods. The clinical data from the baseline visit include demographics as well as the cognitive measures under the Severe Impairment Battery (SIB) and Down Syndrome Mental Status Examina-tion (DS-MSE). Biomarker distributions are described with strong statistical associations observed with participant age. The biomarker data contributes to understanding DS-AD across the spectrum of disease. Collectively, the biomarker data show evidence of DS-AD progression beginning at ap-proximately 40 years of age. Exploring these data across the full LIFE-DSR longitudinal study population will be an important resource in understanding the onset, progression, and clinical profiles of DS-AD pathophysiology.
AB - With improved healthcare, the Down syndrome (DS) population is both growing and aging rapidly. However, with longevity comes a very high risk of Alzheimer’s disease (AD). The LIFE-DSR study (NCT04149197) is a longitudinal natural history study recruiting 270 adults with DS over the age of 25. The study is designed to characterize trajectories of change in DS-associated AD (DS-AD). The current study reports its cross-sectional analysis of the first 90 subjects enrolled. Plasma biomarkers phosphorylated tau protein (p-tau), neurofilament light chain (NfL), amyloid β peptides (Aβ1-40, Aβ1-42), and glial fibrillary acidic protein (GFAP) were undertaken with previously published methods. The clinical data from the baseline visit include demographics as well as the cognitive measures under the Severe Impairment Battery (SIB) and Down Syndrome Mental Status Examina-tion (DS-MSE). Biomarker distributions are described with strong statistical associations observed with participant age. The biomarker data contributes to understanding DS-AD across the spectrum of disease. Collectively, the biomarker data show evidence of DS-AD progression beginning at ap-proximately 40 years of age. Exploring these data across the full LIFE-DSR longitudinal study population will be an important resource in understanding the onset, progression, and clinical profiles of DS-AD pathophysiology.
KW - Alzheimer’s disease
KW - Amyloid β peptide
KW - Blood biomarkers
KW - Down syndrome
KW - Glial fibrillary acidic protein
KW - Neurofilament light chain
KW - Phosphorylated tau protein
UR - http://www.scopus.com/inward/record.url?scp=85113191812&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85113191812&partnerID=8YFLogxK
U2 - 10.3390/jcm10091907
DO - 10.3390/jcm10091907
M3 - Article
AN - SCOPUS:85113191812
VL - 10
JO - Journal of Clinical Medicine
JF - Journal of Clinical Medicine
IS - 9
M1 - 1907
ER -